Current Report Filing (8-k)
23 June 2022 - 8:01PM
Edgar (US Regulatory)
0000764195
false
VBI Vaccines Inc/BC
0000764195
2022-06-22
2022-06-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): June 22, 2022
VBI
VACCINES INC.
(Exact
name of registrant as specified in its charter)
British
Columbia, Canada |
|
001-37769 |
|
N/A |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
160
Second Street, Floor 3
Cambridge,
Massachusetts |
|
02142 |
(Address
of principal executive offices) |
|
(Zip
Code) |
(617)
830-3031
(Registrant’s
telephone number, including area code)
N/A
(Former
Name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of exchange on which registered |
Common
Shares, no par value per share |
|
VBIV |
|
The
NASDAQ Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.07 Submission of Matters to a Vote of Security Holders.
On
June 22, 2022, VBI Vaccines Inc. (the “Company”) held its 2022 Annual General Meeting of Shareholders (the “Annual
Meeting”). At the Annual Meeting, the shareholders voted to: (1) set the number of directors of the Company at eight (8); (2) elect
the nominated directors of the Company to serve until the next annual meeting or until the appointment or election and qualification
of their successors; and (3) approve the appointment of EisnerAmper LLP as the Company’s independent registered public accounting
firm until the next annual meeting of shareholders and authorize the audit committee (the “Audit Committee”) of the board
of directors of the Company to fix EisnerAmper LLP’s remuneration, as set forth in the Company’s definitive proxy statement
filed with the U.S. Securities and Exchange Commission on April 29, 2022 (the “Proxy Statement”). Each of these proposals
is described in more detail in the Proxy Statement.
At
the beginning of the Annual Meeting, there were 179,537,122 common shares present at the Annual Meeting in person or by proxy, which
represented 69.52% of the outstanding common shares entitled to vote at the Annual Meeting and which constituted a quorum for the transaction
of business. Holders of the Company’s common shares were entitled to one vote for each share held as of the close of business on
April 25, 2022, the record date for the Annual Meeting.
The
voting results on these proposals were as follows:
Proposal
1: Set the number of directors of the Company at eight
Votes For | |
Votes Against | |
Abstentions | |
Broker Non-Votes |
90,957,682 | |
2,318,677 | |
0 | |
86,045,763 |
Proposal
2: Election of eight directors
Director | |
Votes For | |
Withheld | |
Broker Non-Votes |
Steven Gillis | |
76,989,942 | |
16,286,418 | |
86,045,762 |
Linda Bain | |
68,460,867 | |
24,815,492 | |
86,045,763 |
Jeffery R. Baxter | |
84,987,022 | |
8,289,337 | |
86,045,763 |
Damian Braga | |
84,721,290 | |
8,555,070 | |
86,045,762 |
Joanne Cordeiro | |
90,821,594 | |
2,454,765 | |
86,045,763 |
Michel De Wilde | |
84,830,581 | |
8,445,778 | |
86,045,763 |
Blaine H. McKee | |
91,077,164 | |
2,199,195 | |
86,045,763 |
Christopher McNulty | |
84,405,251 | |
8,871,108 | |
86,045,763 |
Each
of the eight nominees for director was elected to serve until the next annual meeting of shareholders and until his or her successor
has been elected and qualified, or until his or her earlier death, resignation, or removal.
Proposal
3: Approval of the appointment of EisnerAmper LLP as the independent registered public accounting firm of the Company until the next
annual meeting of shareholders and authorize the Audit Committee to fix EisnerAmper LLP’s remuneration
Votes For | |
Votes Against | |
Abstentions | |
Broker Non-Votes |
175,846,165 | |
0 | |
3,475,956 | |
1 |
The
shareholders approved the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm until the
next annual meeting of shareholders and authorized the Audit Committee to fix EisnerAmper LLP’s remuneration.
The
results reported above are final voting results. No other matters were considered or voted upon at the Annual Meeting.
Item
8.01 Other Events.
On
June 22, 2022, the Company issued a press release announcing the voting results from the Annual Meeting. A copy of the press release
is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
VBI
Vaccines Inc. |
|
|
Date:
June 22, 2022 |
By: |
/s/
Jeffrey R. Baxter |
|
|
Jeffrey
R. Baxter |
|
|
President
and Chief Executive Officer |
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Apr 2024 to May 2024
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From May 2023 to May 2024